ClinicalTrials.gg
TerminatedNCT01522443COMET-2Updated May 23, 2018Results posted

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

A Phase 3 interventional study of cabozantinib and mitoxantrone in Prostate Cancer, Castration Resistant Prostate Cancer and Pain, sponsored by Exelixis. Terminated at 82 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-23.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Why this study was terminated
Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.

Enrollment
6th of 23
119 · median 33
Started
2012
with 5 others
Phase 3
4 of 23
1 open now
Registered
3rd of 23
by date
Lead sponsor
6 of 23
Exelixis

Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 6 that started in 2012, is one of 4 in phase 3, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cabozantinib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated by lack of resolution of lesions on bone scan with these agents) or the pain associated with these metastases.

This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and bone scan response in men with CRPC.

03

Conditions studied

  • Prostate Cancer
  • Castration Resistant Prostate Cancer
  • Pain
  • Prostatic Neoplasms

Keywords

  • prostate cancer
  • castration resistant prostate cancer
  • bone pain
  • CRPC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of castration resistant prostate cancer (serum testosterone less than 50 ng/dL).
  • Evidence of bone related to prostate cancer on bone scans.
  • Documented pain from bone metastases that requires opioid narcotic intervention.
  • Adopted a narcotic regimen that consists of one sustained release opioid agent taken daily for chronic pain and one immediate release opioid agent for breakthrough pain.
  • Received prior docetaxel and either abiraterone or MDV3100 treatment and has evidence of investigator assessed prostate cancer progression on each agent independently.
  • Maintenance of LHRH agonist or antagonist unless treated with orchiectomy.
  • Recovered from toxicities related to any prior treatments, unless the toxicities are clinically non significant or easily manageable.
  • Adequate organ and marrow function.
  • A left-ventricular (LVEF) of >/= 50% assessed by echocardiogram or MUGA (multigated acquisition scan).
  • Capable of understanding and complying with the protocol requirements (including having the ability to access an interactive voice recognition system and self-report pain and narcotic use) and signed the form.
  • Sexually active fertile patients and their partners must agree to use medically accepted methods of (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 3 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with cabozantinib or mitoxantrone.
  • Treatment with docetaxel, abiraterone, or MDV3100 in the last 2 weeks; or with any other type of cytotoxic or anticancer agent in the last 2 weeks.
  • Radiation therapy in the last 4 weeks (includes radiation targeting bone ), radionuclide treatment in the last 6 weeks, or radiation therapy to the thoracic cavity (unless radiation targets bone metastases) in the past 3 months.
  • Treatment with serotonergic psychiatric medication(s) in the last 2 weeks (5 weeks for fluoxetine).
  • Known or uncontrolled epidural disease.
  • Requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or FXa (coagulation factor X) inhibitors, or antiplatelet agents (eg, clopidogrel). Low dose aspirin (above low dose levels for cardioprotection per local applicable guidelines), low-dose warfarin (≤ 1 mg/day), and prophylactic low molecular weight heparin are permitted.
  • Uncontrolled, significant intercurrent illness including, but not limited to, cardiovascular disorders, gastrointestinal disorders, active infections, non-healing wounds, recent surgery.
  • hematemesis or hemoptysis of > 0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage in the last 3 months, or history of other significant bleeding in the past 6 months.
  • Cavitating pulmonary lesion(s) or a lesion invading or encasing a major blood vessel.
  • interval (QTc) > 500 ms in the last 4 weeks.
  • Unable to swallow capsules or tablets or tolerate infusions.
  • Previously-identified allergy or to components of the study treatment formulations investigator or designee.
  • History of another (except non-melanoma skin cancer, adequately treated stage I colon cancer, superficial transitional carcinoma of the bladder) in the past 2 years.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Cabozantinib

    Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules. There will be a maximum of 10 infusions for mitoxantrone placebo.

    Drug: cabozantinib

  • Active comparator
    Mitoxantrone/prednisone

    Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets. There will be a maximum of 10 infusions for mitoxantrone.

    Drug: mitoxantrone · Drug: prednisone

Interventions

  • Tablets taken orally once daily.

  • Given by IV once every 3 weeks.

  • Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.

06

What researchers measure

Primary outcomes

  1. Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported

    The pre-specified primary analysis of Pain Response at Week 6 confirmed at Week 12 was defined as ≥ 30% from baseline in the average daily worst pain intensity score during a 7-day reporting period, with neither a concomitant increase in average daily use of any opioid narcotic type, nor addition of any new opioid narcotic type, relative to baseline. Pain Progression at a given time point is defined as ≥ 30% increase compared with baseline in the average daily worst pain intensity score during a 7-day reporting period or either an increase in the average daily use of any type of opioid narcotic or addition of a new opioid narcotic type compared with baseline.

    Time frame: Pain response was measured at Week 6 and Week 12 by self-reports of subjects

Secondary outcomes

  1. Bone Scan Response (BSR)

    BSR is defined as \>=30% in the bone scan lesion area (BSLA) compared with baseline. Bones scans were evaluated by an independent radiology facility (IRF) for response.

    Time frame: BSR was measured at the end of Week 12 as determined by the IRF

  2. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death (due to any cause). Participants that had not died were censored at last known date alive. The analyses for OS occurred after 78/196 deaths (40% of the total required for the pre-specified primary analysis of OS). The data cut-off date was 06 October 2014. Median OS was calculated using Kaplan-Meier estimates.

    Time frame: OS was measured at the time of randomization until 78 deaths

07

Results

Posted May 23, 2018
Limitations and caveats
Enrollment was stopped before planned study population size of 246 was reached (only 119 enrolled).

Participant flow

First patient enrolled: 15 March 2012, Data cut off date: 06 October 2014. The study was terminated by the Sponsor after 119 subjects were enrolled which was less than the planned sample size of 246 subjects.

Participant flow — Overall Study
MilestoneCabozantinibMitoxantrone/Prednisone
Started6158
Completed83
Not completed5355
Withdrew: No longer receiving clinical benefit3628
Withdrew: Adverse event1015
Withdrew: Withdrawal by subject58
Withdrew: No study treatment given11
Withdrew: Other13

Outcome measures

PrimaryPain Response at Week 6 Confirmed at Week 12, Week 12 Reported

The pre-specified primary analysis of Pain Response at Week 6 confirmed at Week 12 was defined as ≥ 30% from baseline in the average daily worst pain intensity score during a 7-day reporting period, with neither a concomitant increase in average daily use of any opioid narcotic type, nor addition of any new opioid narcotic type, relative to baseline. Pain Progression at a given time point is defined as ≥ 30% increase compared with baseline in the average daily worst pain intensity score during a 7-day reporting period or either an increase in the average daily use of any type of opioid narcotic or addition of a new opioid narcotic type compared with baseline.

Time frame:
Pain response was measured at Week 6 and Week 12 by self-reports of subjects
Reported as:
Number · percentage of responders
Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported
percentage of respondersCabozantinibMitoxantrone/Prednisone
Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported15 (5.9 to 24)17 (7.5 to 27)
Statistical analysis
  • Cabozantinib vs Mitoxantrone/Prednisone · Cochran-Mantel-Haenszel · p = 0.773The Cochran-Mantel-Haenszel (CMH) was stratified by the Eastern Cooperative Oncology Group performance status and prior cabazitaxel use.
SecondaryBone Scan Response (BSR)

BSR is defined as \>=30% in the bone scan lesion area (BSLA) compared with baseline. Bones scans were evaluated by an independent radiology facility (IRF) for response.

Time frame:
BSR was measured at the end of Week 12 as determined by the IRF
Reported as:
Number · percentage of responders
Bone Scan Response (BSR)
percentage of respondersCabozantinibMitoxantrone/Prednisone
Bone Scan Response (BSR)31 (20 to 43)5.2 (0 to 11)
Statistical analysis
  • Cabozantinib vs Mitoxantrone/Prednisone · Cochran-Mantel-Haenszel · p = <0.001The Cochran-Mantel-Haenszel (CMH) Test was stratified by baslined Eastern Cooperative Oncology Group performance status and prior cabazitaxel use.
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to the date of death (due to any cause). Participants that had not died were censored at last known date alive. The analyses for OS occurred after 78/196 deaths (40% of the total required for the pre-specified primary analysis of OS). The data cut-off date was 06 October 2014. Median OS was calculated using Kaplan-Meier estimates.

Time frame:
OS was measured at the time of randomization until 78 deaths
Reported as:
Median · months
Overall Survival (OS)
monthsCabozantinibMitoxantrone/Prednisone
Overall Survival (OS)9.0 (6.80 to 11.56)7.9 (5.26 to 9.10)
Statistical analysis
  • Cabozantinib vs Mitoxantrone/Prednisone · Log Rank · p = 0.121 · Hazard ratio (hr): 0.70 · 95% CI 0.44 to 1.10The Log-Rank Test was stratified by baseline Eastern Cooperative Oncology Group performance status and prior cabazitaxel use.

Adverse events

Collected over Up to 95 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib—16/60 (26.7%)60/60 (100%)
Mitoxantrone/Prednisone—15/57 (26.3%)57/57 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventCabozantinibMitoxantrone/Prednisone
Febrile neutropeniaBlood and lymphatic system disorders0/604/57
NeutropeniaBlood and lymphatic system disorders0/603/57
Abdominal painGastrointestinal disorders0/602/57
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/602/57
NauseaGastrointestinal disorders2/601/57
PneumoniaInfections and infestations2/601/57
DiarrhoeaGastrointestinal disorders1/601/57
VomitingGastrointestinal disorders1/601/57
AstheniaGeneral disorders1/601/57
PyrexiaGeneral disorders1/601/57
Most frequent other events
Showing 10 of 41
Most frequent other events
EventCabozantinibMitoxantrone/Prednisone
NauseaGastrointestinal disorders38/6024/57
FatigueGeneral disorders34/6027/57
Decreased appetiteMetabolism and nutrition disorders28/6023/57
DiarrhoeaGastrointestinal disorders27/6017/57
Weight decreasedInvestigations25/608/57
ConstipationGastrointestinal disorders24/6019/57
VomitingGastrointestinal disorders23/6019/57
HypertensionVascular disorders18/600/57
AstheniaGeneral disorders14/604/57
DepressionPsychiatric disorders14/608/57

Baseline characteristics

Age, Customized
Age, Customized(participants)CabozantinibMitoxantrone/PrednisoneTotal
<65 years242650
65 to <75 years302656
75 to <85 years7613
Sex: Female, Male
Sex: Female, Male(Participants)CabozantinibMitoxantrone/PrednisoneTotal
Female000
Male6158119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CabozantinibMitoxantrone/PrednisoneTotal
Hispanic or Latino202
Not Hispanic or Latino5757114
Unknown or Not Reported213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)CabozantinibMitoxantrone/PrednisoneTotal
American Indian/Alaska Native101
Asian134
Black/African-American8311
Multiple101
White4951100
Not Reported011
Other101
Geographic Region
Geographic Region(participants)CabozantinibMitoxantrone/PrednisoneTotal
North America443680
Europe81321
Asia9918
ECOG Performance Status (per IVRS/IWRS)
ECOG Performance Status (per IVRS/IWRS)(participants)CabozantinibMitoxantrone/PrednisoneTotal
0-1 (normal to symptoms, but ambulatory)5352105
≥2 (ambulatory to incapable of self-care/death)8614
Randomization Stratification Factors (per IVRS/IWRS)
Randomization Stratification Factors (per IVRS/IWRS)(participants)CabozantinibMitoxantrone/PrednisoneTotal
ECOG = 0-1 and prior cabazitaxel: yes181836
ECOG = 0-1 and prior cabazitaxel: no353469
ECOG ≥ 2 and prior cabazitaxel: yes7613
ECOG ≥ 2 and prior cabazitaxel: no101
Time from initial diagnosis to randomization
Time from initial diagnosis to randomization(years)CabozantinibMitoxantrone/PrednisoneTotal
Median4.7 (0 to 18)5.3 (0 to 16)5.0 (0 to 18)

8 further baseline measures are reported on the registry.

08

Study locations

82 sites
  • Scottsdale, Arizona 85258, United States
  • La Jolla, California 92093, United States
  • Los Angeles, California 90024, United States
  • Los Angeles, California 90073, United States
  • Marina Del Rey, California 90292, United States
  • San Diego, California 92123, United States
  • San Francisco, California 94115, United States
  • Santa Barbara, California 93105, United States
  • Stanford, California 94305, United States
  • Aurora, Colorado 80012, United States
  • Littleton, Colorado 80122, United States
  • Washington, District of Columbia 20037, United States
  • Boca Raton, Florida 33486, United States
  • Athens, Georgia 30607, United States
  • Chicago, Illinois 60611, United States
  • Indianapolis, Indiana 46202, United States
  • Iowa City, Iowa 52242, United States
  • Westwood, Kansas 66025, United States
  • Louisville, Kentucky 40202, United States
  • New Orleans, Louisiana 70112, United States
  • Baltimore, Maryland 21231, United States
  • Detroit, Michigan 48201, United States
  • Detroit, Michigan 48202, United States
  • Minneapolis, Minnesota 55455, United States
  • Tupelo, Mississippi 38801, United States
  • Saint Louis, Missouri 63110, United States
  • Omaha, Nebraska 68198, United States
  • Las Vegas, Nevada 89109, United States
  • New Brunswick, New Jersey, United States
  • Buffalo, New York 14263, United States
  • New York, New York 10019, United States
  • New York, New York 10022, United States
  • New York, New York 10065, United States
  • Chapel Hill, North Carolina 27516, United States
  • Durham, North Carolina 27710, United States
  • Raleigh, North Carolina 27607, United States
  • Cleveland, Ohio 44195, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Pittsburgh, Pennsylvania 15232, United States
  • Watertown, South Dakota 57201, United States
  • Memphis, Tennessee 38120, United States
  • Nashville, Tennessee 37203, United States
  • Dallas, Texas 75246, United States
  • Round Rock, Texas 78681, United States
  • Salt Lake City, Utah 84112, United States
  • Norfolk, Virginia 23502, United States
  • Seattle, Washington 98104, United States
  • Madison, Wisconsin 53705, United States
  • Milwaukee, Wisconsin 53226, United States
  • Concord, New South Wales 2139, Australia
  • Darlinghurst, New South Wales 2010, Australia
  • Kogarah, New South Wales 2217, Australia
  • Port Macquarie, New South Wales 2444, Australia
  • Randwick, New South Wales 2031, Australia
  • Wahroonga, New South Wales 2076, Australia
  • Milton, Queensland 4064, Australia
  • South Brisbane, Queensland 4101, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Box Hill, Victoria 3128, Australia
  • Wodonga, Victoria 3690, Australia
  • Subiaco, Western Australia, Australia
  • Kelowna, British Columbia V1Y 5L3, Canada
  • Vancouver, British Columbia V57 4E6, Canada
  • London, Ontario N6A 4L6, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Dublin, 24, Ireland
  • Dublin, 7, Ireland
  • Bath, England BA1 3NG, United Kingdom
  • Cambridge, England CB2 0QQ, United Kingdom
  • Leeds, England LS9 7TF, United Kingdom
  • London, England NW1 2PG, United Kingdom
  • London, England SE1 9RT, United Kingdom
  • London, England W12 0HS, United Kingdom
  • Manchester, England M20 4BX, United Kingdom
  • Sutton, England SM2 5PT, United Kingdom
  • Wirral, England CH63 4JY, United Kingdom
  • Aberdeen, Scotland AB25 2ZN, United Kingdom
  • Edinburgh, Scotland EH4 2XU, United Kingdom
  • Glasgow, Scotland G12 0YN, United Kingdom
  • Inverness, Scotland RO17, United Kingdom
  • Belfast, United Kingdom
09

References and documents

Publications

  • Thanarajasingam G, Basch E, Mead-Harvey C, Bennett AV, Mazza GL, Schwab G, Roydhouse J, Rogak LJ, Dueck AC. An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. Value Health. 2022 Jul;25(7):1081-1086. doi: 10.1016/j.jval.2021.11.1368. Epub 2022 Jan 3. PubMed 35779938 ↗
  • Mazza GL, Petersen MM, Ginos B, Langlais BT, Heon N, Gounder MM, Mahoney MR, Zoroufy AJ, Schwartz GK, Rogak LJ, Thanarajasingam G, Basch E, Dueck AC. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. Qual Life Res. 2022 Apr;31(4):1069-1080. doi: 10.1007/s11136-021-02968-1. Epub 2021 Aug 21. Erratum In: Qual Life Res. 2022 Apr;31(4):1081. doi: 10.1007/s11136-021-03000-2. PubMed 34420143 ↗
  • Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials. 2021 Feb;18(1):104-114. doi: 10.1177/1740774520975120. Epub 2020 Dec 1. PubMed 33258687 ↗
  • Dueck AC, Scher HI, Bennett AV, Mazza GL, Thanarajasingam G, Schwab G, Weitzman AL, Rogak LJ, Basch E. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncol. 2020 Feb 1;6(2):e193332. doi: 10.1001/jamaoncol.2019.3332. Epub 2020 Feb 13. PubMed 31556911 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Oct 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2018, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 31, 2012
Start
Mar 2012
Primary completionActual
Oct 2014
CompletionActual
Jan 13, 2015
Results first posted
May 23, 2018
Last update
May 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01522443
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jan 31, 2012
Start date
Mar 2012
Primary completion
Oct 2014
Completion
Jan 13, 2015
Results posted
May 23, 2018
Last update
May 23, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion